S&P 500
7,791.18
-16.06
-0.21%
Dow
51,763.33
-87.22
-0.17%
Nasdaq
27,168.51
-77.39
-0.28%
NYSE Composite
23,952.50
+13.40
+0.06%
Russell 2000
2,780.83
-26.15
-0.93%
VIX
15.33
+0.49
+3.30%
SNDX · Syndax Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$13.64
-2.90
(-17.53%)
● Market open
DAY'S RANGE
$13.64
$13.49
$14.66
52-WEEK RANGE
$13.64
$12.99
$25.59
What's happening
- SNDX is down 17.53% today, trading at $13.64. — Live quote
- Volume today (143,511) is well below its 3-month average of 1,798,900. (Finnhub fundamentals)
- Reports earnings on 2026-10-29, 16 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.55 actual vs. $-0.45 estimated (-21.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-09-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
SNDX
-19.13%
vs S&P 500
-33.31%
1-YEAR RETURN
SNDX
+4.88%
vs S&P 500
-11.13%
6-MONTH RETURN
SNDX
-31.05%
3-MONTH RETURN
SNDX
-28.04%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.55
Est. $-0.45
MISS -21.9%
2026-04-26 (Q1 2026)
$-0.48
Est. $-0.59
BEAT +19.2%
2026-01-26 (Q4 2025)
$-0.78
Est. $-0.60
MISS -30.9%
2025-10-26 (Q3 2025)
$-0.70
Est. $-0.73
BEAT +4.2%
Valuation Measures & Ratios
Enterprise Value4$1.72B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)5.84
Price / Book7128.29
EV4 / Revenue6.83
EV4 / EBITDA1525.79
Profit Margin-87.52%
Operating Margin-76.98%
Return on Equity (ROE8)-372.94%
Return on Assets (ROA9)-39.11%
Avg Volume (3M)1,798,900
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.96B | $2.08B | $1.33B | $811.5M | $1.06B |
| P/E | -8.73 | -7.99 | -4.43 | -2.63 | -3.44 |
| Price/Sales | 8.85 | 12.31 | 11.47 | 10.97 | 29.52 |
| Price/Book | 129.88 | 49.92 | 11.56 | 5.16 | 4.95 |
| EV/Revenue | 8.92 | 13.61 | 13.27 | 13.97 | 34.57 |
| ROE | -1487.50% | -624.86% | -261.23% | -196.21% | -143.88% |
| ROA | -31.92% | -55.02% | -54.65% | -51.81% | -48.30% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short18,234,880
Change from Prior Settlement-11.74%
% of Float—
Days to Cover (Short Ratio)8.47
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 91.8% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +4.9%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -87.5%. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-04; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on SNDX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72.8M | $64.9M | $45.9M | $38.0M | $20.0M | $12.5M | $3.5M | $0 |
| Operating income | -$40.0M | -$34.2M | -$57.4M | -$69.4M | -$83.8M | -$89.6M | -$74.2M | -$79.5M |
| Net income | -$49.4M | -$42.7M | -$60.7M | -$71.8M | -$84.8M | -$84.1M | -$68.1M | -$72.4M |
| EPS (diluted) | $-0.55 | $-0.48 | $-0.70 | $-0.83 | $-0.98 | $-0.98 | $-0.80 | $-0.85 |
| EPS (basic) | $-0.55 | $-0.48 | $-0.70 | $-0.83 | $-0.98 | $-0.98 | $-0.80 | $-0.85 |
| Operating margin | -$55 | -$53 | -$125 | -$183 | -$418 | -$717 | -$2.1K | — |
| Net margin | -$68 | -$66 | -$132 | -$189 | -$423 | -$673 | -$1.9K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $703.7M | $472.7M | $529.7M | $551.8M | $596.1M | $640.7M | $724.8M | $425.8M |
| Total liabilities | $688.6M | $431.0M | $465.1M | $436.4M | $438.7M | $425.6M | $436.7M | $59.4M |
| Stockholders' equity | $15.1M | $41.6M | $64.6M | $115.4M | $157.4M | $215.1M | $288.1M | $366.4M |
| Total current assets | $675.0M | $471.2M | $528.1M | $529.8M | $531.7M | $548.8M | $603.1M | $414.8M |
| Total current liabilities | $99.7M | $86.2M | $120.1M | $114.2M | $113.0M | $94.6M | $103.5M | $59.4M |
| Cash & equivalents | $336.5M | $130.9M | $134.9M | $116.8M | $108.6M | $154.0M | $154.1M | $133.0M |
| Marketable securities (current) | $211.4M | $221.2M | $259.1M | $319.2M | $346.6M | $358.2M | $418.8M | $256.6M |
| Accounts receivable | — | — | $38.0M | — | — | — | $7.6M | — |
| Inventory | $33.2M | $34.9M | $32.8M | $25.0M | $17.7M | $4.7M | $366.0K | — |
| Other current assets | — | — | — | — | — | — | — | $3.5M |
| Marketable securities (non-current) | $27.2M | — | $0 | $20.1M | $62.6M | $89.9M | $119.5M | $10.0M |
| Property, plant & equipment | $212.0K | $177.0K | $181.0K | $128.0K | $0 | $0 | $0 | $0 |
| Other non-current assets | — | — | — | — | — | — | $0 | $0 |
| Accounts payable | $4.9M | $10.8M | $16.6M | $13.8M | $17.4M | $10.0M | $11.6M | $4.9M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | $350.0M | $350.0M | $350.0M | $327.1M | $330.6M | $335.9M | $337.9M | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K | $9.0K |
| Retained earnings | -$1.60B | -$1.55B | -$1.51B | -$1.44B | -$1.38B | -$1.31B | -$1.22B | -$1.13B |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$30.3M | -$50.3M | -$69.5M | -$70.5M | -$87.8M | -$95.2M | -$57.4M | -$62.3M |
| Investing cash flow | -$16.9M | $38.4M | $81.6M | $72.4M | $41.9M | $94.1M | -$269.0M | $86.8M |
| Financing cash flow | $252.8M | $7.9M | $5.9M | $6.3M | $551.0K | $930.0K | $347.4M | $3.1M |
| Free cash flow | — | — | -$69.7M | — | — | — | -$57.4M | — |
| Capital expenditures | — | — | $187.0K | — | — | — | $0 | — |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $14.0M | $12.1M | $11.3M | $12.1M | $13.8M | $10.4M | $12.3M | $11.9M |
| Change in accounts receivable | $7.2M | -$120.0K | $12.6M | $5.9M | $3.7M | $8.1M | $7.6M | $0 |
| Change in inventory | -$1.8M | $2.1M | $7.8M | $7.2M | $12.9M | $4.2M | $366.0K | $0 |
| Change in accounts payable | -$6.0M | -$5.7M | $2.8M | -$3.5M | $7.3M | -$1.6M | $6.7M | -$6.7M |
| Debt repaid | — | — | — | — | — | — | — | — |
| Other financing activities | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M |
| EPS (diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.46 |
| EPS (basic) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.48 |
| Operating margin | -$158 | -$1.4K | — | — | $19 |
| Net margin | -$166 | -$1.3K | — | — | $18 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M |
| Stockholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M |
| Total current assets | $528.1M | $603.1M | $580.9M | $489.8M | $448.4M |
| Total current liabilities | $120.1M | $103.5M | $58.1M | $29.1M | $20.7M |
| Cash & equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M |
| Marketable securities (current) | $259.1M | $418.8M | $275.3M | $401.4M | $218.0M |
| Accounts receivable | $38.0M | $7.6M | $0 | — | — |
| Inventory | $32.8M | $366.0K | $0 | — | — |
| Marketable securities (non-current) | $0 | $119.5M | $29.8M | $5.5M | $0 |
| Property, plant & equipment | $181.0K | $0 | $8.0K | $20.0K | $278.0K |
| Other non-current assets | — | $0 | $463.0K | $807.0K | $0 |
| Accounts payable | $16.6M | $11.6M | $10.0M | $4.3M | $5.7M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | $350.0M | $337.9M | $0 | — | — |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $9.0K | $9.0K | $8.0K | $7.0K | $6.0K |
| Retained earnings | -$1.51B | -$1.22B | -$902.4M | -$693.0M | -$543.7M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M |
| Investing cash flow | $290.0M | -$219.8M | $117.6M | -$186.2M | -$40.9M |
| Financing cash flow | $13.7M | $353.4M | $264.1M | $172.3M | $118.5M |
| Free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | $29.0M |
| Capital expenditures | $187.0K | $0 | $0 | $0 | $129.0K |
| Share-based compensation | $47.5M | $43.0M | $31.0M | $16.0M | $13.3M |
| Change in accounts receivable | $30.4M | $7.6M | $0 | $0 | — |
| Change in inventory | $32.1M | $366.0K | $0 | $0 | — |
| Change in accounts payable | $5.0M | $1.7M | $5.6M | -$1.3M | $2.2M |
| Debt repaid | — | — | — | — | — |
| Other financing activities | — | — | — | — | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding SNDX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers90.2%
Shares Outstanding88,991,317
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,020,006 | $197.2M | 10.14% | +9.3% | 2026-08-07 |
| Kynam Capital Management, LP | 8,050,959 | $176.0M | 9.05% | +0.0% | 2026-08-14 |
| Goldman Sachs Group Inc | 5,861,265 | $128.1M | 6.59% | +17.3% | 2026-08-14 |
| State Street Corp | 5,658,424 | $123.7M | 6.36% | +27.7% | 2026-08-07 |
| Bank Of America Corp /De/ | 4,045,094 | $88.4M | 4.55% | -4.8% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,927,892 | $85.9M | 4.41% | +2.8% | 2026-06-30 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3,779,900 | $82.6M | 4.25% | +0.0% | 2026-08-14 |
| Eversept Partners, LP | 2,798,210 | $61.2M | 3.14% | -3.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,584,136 | $56.5M | 2.90% | +19.8% | 2026-08-12 |
| Hood River Capital Management LLC | 2,564,279 | $56.1M | 2.88% | +8.9% | 2026-08-06 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 2,500,000 | $54.6M | 2.81% | +0.0% | 2026-08-14 |
| Franklin Templeton Inc | 2,286,499 | $50.0M | 2.57% | +6.3% | 2026-08-04 |
| MILLENNIUM MANAGEMENT LLC | 2,053,960 | $44.9M | 2.31% | +929.4% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,921,796 | $42.0M | 2.16% | +10.6% | 2026-06-30 |
| UBS Group AG | 1,893,750 | $41.4M | 2.13% | +64.2% | 2026-08-13 |
| Elmind Capital, LP | 1,855,000 | $40.6M | 2.08% | +0.0% | 2026-08-14 |
| BNP Paribas Asset Management Holding S.A. | 1,790,173 | $39.1M | 2.01% | +3.3% | 2026-08-12 |
| Candriam S.C.A. | 1,696,040 | $37.0M | 1.91% | +83.3% | 2026-08-13 |
| Soleus Capital Management, L.P. | 1,628,039 | $35.6M | 1.83% | -5.7% | 2026-08-11 |
| TWO SIGMA INVESTMENTS, LP | 1,578,125 | $34.5M | 1.77% | -0.1% | 2026-08-07 |
| ORBIMED ADVISORS LLC | 1,542,000 | $33.7M | 1.73% | +60.2% | 2026-08-14 |
| Nuveen, LLC | 1,364,575 | $29.8M | 1.53% | -8.7% | 2026-08-11 |
| MPM BioImpact LLC | 1,333,523 | $29.2M | 1.50% | -0.5% | 2026-08-14 |
| Aisling Capital Management LP | 1,316,806 | $28.8M | 1.48% | +0.0% | 2026-08-13 |
| Woodline Partners LP | 1,250,760 | $27.3M | 1.41% | +0.0% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-05-16 to 2026-07-08
Recent transactions
- Insiders have net sold 105,914 shares over the last 182 days, across 0 purchases and 5 sales.
- Most recent: Metzger Michael A (Chief Executive Officer) — Option exercise of 32,375 shares on 2026-07-08.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)105,914 sh(5 txns)
Net Shares-105,914
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | Option exercise | 2026-07-08 | 32,375 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Option exercise | 2026-06-12 | 31,235 |
| Goldan Keith A. | Chief Financial Officer | Open market sale | 2026-06-01 | 1,177 |
| Jarrett Jennifer | Reporting person | Grant / award | 2026-02-04 | 24,000 |
| Huber Martin H. Jr. | Reporting person | Grant / award | 2026-02-04 | 24,000 |
| Podlesak Dennis | Reporting person | Grant / award | 2026-02-04 | 48,000 |
| Rizo Aleksandra | Reporting person | Grant / award | 2026-02-04 | 24,000 |
| Katkin Keith | Reporting person | Grant / award | 2026-02-04 | 24,000 |
| Legault Pierre | Reporting person | Grant / award | 2026-02-04 | 24,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-08 | Metzger Michael A | Chief Executive Officer | Option exercise | 32,375 | $6.38 |
| 2026-07-08 | Metzger Michael A | Chief Executive Officer | Open market sale | 32,375 | $24.24 |
| 2026-06-12 | Botwood Nicholas A.J. | Head of R&D, CMO | Option exercise | 31,235 | $13.82 |
| 2026-06-12 | Botwood Nicholas A.J. | Head of R&D, CMO | Open market sale | 31,235 | $18.14 |
| 2026-06-11 | Botwood Nicholas A.J. | Head of R&D, CMO | Option exercise | 22,515 | $13.82 |
| 2026-06-11 | Botwood Nicholas A.J. | Head of R&D, CMO | Open market sale | 34,280 | $18.00 |
| 2026-06-01 | Goldan Keith A. | Chief Financial Officer | Open market sale | 1,177 | $18.99 |
| 2026-06-01 | Metzger Michael A | Chief Executive Officer | Open market sale | 6,847 | $18.99 |
| 2026-02-09 | Metzger Michael A | Chief Executive Officer | Open market sale | 17,159 | $21.03 |
| 2026-02-09 | Goldan Keith A. | Chief Financial Officer | Open market sale | 3,410 | $21.03 |
| 2026-02-06 | Metzger Michael A | Chief Executive Officer | Open market sale | 7,412 | $20.62 |
| 2026-02-06 | Goldan Keith A. | Chief Financial Officer | Open market sale | 2,082 | $20.62 |
| 2026-02-04 | Metzger Michael A | Chief Executive Officer | Grant / award | 73,000 | $0.00 |
| 2026-02-04 | Metzger Michael A | Chief Executive Officer | Grant / award | 144,600 | $0.00 |
| 2026-02-04 | Goldan Keith A. | Chief Financial Officer | Grant / award | 21,500 | $0.00 |
| 2026-02-04 | Goldan Keith A. | Chief Financial Officer | Grant / award | 30,750 | $0.00 |
| 2026-02-04 | Jarrett Jennifer | Reporting person | Grant / award | 24,000 | $0.00 |
| 2026-02-04 | Huber Martin H. Jr. | Reporting person | Grant / award | 24,000 | $0.00 |
| 2026-02-04 | Botwood Nicholas A.J. | Head of R&D, CMO | Grant / award | 24,000 | $0.00 |
| 2026-02-04 | Botwood Nicholas A.J. | Head of R&D, CMO | Grant / award | 36,000 | $0.00 |
| 2026-02-04 | Podlesak Dennis | Reporting person | Grant / award | 48,000 | $0.00 |
| 2026-02-04 | Rizo Aleksandra | Reporting person | Grant / award | 24,000 | $0.00 |
| 2026-02-04 | Katkin Keith | Reporting person | Grant / award | 24,000 | $0.00 |
| 2026-02-04 | Legault Pierre | Reporting person | Grant / award | 24,000 | $0.00 |
| 2026-01-30 | Goldan Keith A. | Chief Financial Officer | Other acquisition/disposition | 1,219 | $8.48 |
| 2025-12-01 | Goldan Keith A. | Chief Financial Officer | Gift | 1,224 | $0.00 |
| 2025-09-08 | Metzger Michael A | Chief Executive Officer | Option exercise | 157,307 | $10.90 |
| 2025-09-08 | Metzger Michael A | Chief Executive Officer | Open market sale | 157,307 | $16.41 |
| 2025-08-18 | Podlesak Dennis | Reporting person | Option exercise | 19,200 | $7.20 |
| 2025-08-18 | Podlesak Dennis | Reporting person | Open market sale | 19,200 | $15.84 |
| 2025-08-15 | Podlesak Dennis | Reporting person | Option exercise | 19,200 | $7.20 |
| 2025-08-15 | Podlesak Dennis | Reporting person | Open market sale | 19,200 | $15.54 |
| 2025-08-14 | Podlesak Dennis | Reporting person | Option exercise | 19,200 | $7.20 |
| 2025-08-14 | Podlesak Dennis | Reporting person | Open market sale | 19,200 | $14.19 |
| 2025-07-31 | Goldan Keith A. | Chief Financial Officer | Other acquisition/disposition | 1,226 | $8.43 |
| 2025-07-16 | Goldan Keith A. | Chief Financial Officer | Open market sale | 1,296 | $9.29 |
| 2025-07-16 | Metzger Michael A | Chief Executive Officer | Open market sale | 7,534 | $9.29 |
| 2025-05-19 | Goldan Keith A. | Chief Financial Officer | Open market purchase | 3,000 | — |
| 2025-05-19 | Huber Martin H. Jr. | Reporting person | Open market purchase | 5,000 | $8.99 |
| 2025-05-19 | Katkin Keith | Reporting person | Open market purchase | 10,000 | $9.11 |
| 2025-05-16 | Botwood Nicholas A.J. | Head of R&D, CMO | Open market purchase | 11,765 | $8.99 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-13 14:19 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-14 | 8-K | 2026-07-14 | View on SEC.gov → |
| 2026-07-09 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-10 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-06-10 | 8-K | 2026-06-10 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-06-02 | 4 | 2026-06-01 | View on SEC.gov → |
| 2026-04-30 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-30 | 8-K | 2026-04-30 | View on SEC.gov → |
Recent news
Headlines about SNDX (Syndax Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Why is Syndax Pharmaceuticals stock sliding today?
Investing.com · 2026-10-13 -
Syndax Pharmaceuticals (NASDAQ:SNDX) Given Buy Rating at HC Wainwright
MarketBeat · 2026-10-13 -
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38
GuruFocus · 2026-10-13 -
Citi reiterates Buy rating on Syndax Pharmaceuticals after stock drop
StreetInsider · 2026-10-13 -
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Benzinga · 2026-10-13 -
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target
Benzinga · 2026-10-13 -
Why UnitedHealth Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 2026-10-13 -
How Trial Failure In IPF At Syndax Pharmaceuticals (SNDX) Has Changed Its Investment Story
Simply Wall Street · 2026-10-13
No headlines in this category right now — try “All”.